The risk of cancer among insulin glargine users in Lithuania: A retrospective population-based study

Jonusas Justinas; Drevinskaitė Mingailė; Linkeviciute-Ulinskiene Donata; Ladukas Adomas; Patašius Aušvydas; Zabulienė Lina; Smailytė Giedrė

doi:10.1515/med-2024-1017

Open Medicine (Oct 2024)

The risk of cancer among insulin glargine users in Lithuania: A retrospective population-based study

Jonusas Justinas,
Drevinskaitė Mingailė,
Linkeviciute-Ulinskiene Donata,
Ladukas Adomas,
Patašius Aušvydas,
Zabulienė Lina,
Smailytė Giedrė

Affiliations

Jonusas Justinas: Laboratory of Cancer Epidemiology, National Cancer Institute, LT-08406, Vilnius, Lithuania
Drevinskaitė Mingailė: Laboratory of Cancer Epidemiology, National Cancer Institute, LT-08406, Vilnius, Lithuania
Linkeviciute-Ulinskiene Donata: The Medical Clinic, Västerås Central Hospital, 72189, Västerås, Sweden
Ladukas Adomas: Laboratory of Cancer Epidemiology, National Cancer Institute, LT-08406, Vilnius, Lithuania
Patašius Aušvydas: Laboratory of Cancer Epidemiology, National Cancer Institute, LT-08406, Vilnius, Lithuania
Zabulienė Lina: Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, 03101, Vilnius, Lithuania
Smailytė Giedrė: Laboratory of Cancer Epidemiology, National Cancer Institute, LT-08406, Vilnius, Lithuania

DOI: https://doi.org/10.1515/med-2024-1017
Journal volume & issue: Vol. 19, no. 1
pp. 1513 – 30

Abstract

Read online

The aim of this study was to determine the association between insulin glargine usage and the potential increase in cancer risk among the Lithuanian population diagnosed with type 2 diabetes mellitus (T2DM).

Published in Open Medicine

ISSN: 2391-5463 (Online)
Publisher: De Gruyter
Country of publisher: Poland
LCC subjects: Medicine
Website: https://www.degruyter.com/journal/key/med/html

About the journal